The introduction of amivantamab offers a important step forward for individuals battling cancers featuring c-MET aberration. This unique antibody, a targeted blocker of both MET kinase and also human epidermal growth factor receptor 2 (HER2), revealed early efficacy in research assessments, particularly in patients whose tumors display detectable c